Foghorn Therapeutics Inc.
NASDAQ: FHTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Adrian H. Gottschalk
- Employees
- 112
- Headquarters
- Cambridge, United States
- IPO year
- 2020
- Market cap
- $239.6M
- Website
- https://foghorntx.com
Loading FHTX…
Loading profile data…Frequently asked questions about FHTX
What does Foghorn Therapeutics Inc. (FHTX) do?
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug develop...
Where does FHTX trade?
Foghorn Therapeutics Inc. (FHTX) trades on the NASDAQ Global Market.
What sector is FHTX in?
Foghorn Therapeutics Inc. (FHTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Foghorn Therapeutics Inc.?
Adrian H. Gottschalk is the chief executive officer of Foghorn Therapeutics Inc. (FHTX).
Where is Foghorn Therapeutics Inc. headquartered?
Foghorn Therapeutics Inc. is headquartered in United States.
Does FHTX pay a dividend?
Foghorn Therapeutics Inc. (FHTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did FHTX go public?
Foghorn Therapeutics Inc. (FHTX) completed its initial public offering in 2020.